How many drugs treat Diabetes mellitus type 1?

Drug Landscape tracks 10 marketed treatments for Diabetes mellitus type 1 (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Diabetes mellitus type 1?

Most recent: Farxiga — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/diabetes-mellitus-type-1.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Diabetes mellitus type 1 — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diabetes mellitus type 1 (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Diabetes mellitus type 1, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Inpefa	SOTAGLIFLOZIN	Lexicon Pharms Inc	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	Sodium/glucose cotransporter 2	2023-01-01
Tzield	TEPLIZUMAB	Provention Bio Inc	CD3-directed Antibody [EPC]	T-cell surface glycoprotein CD3	2022-01-01
Farxiga	DAPAGLIFLOZIN	AstraZeneca	Sodium-Glucose Cotransporter 2 Inhibitor	Sodium/glucose cotransporter 2	2014-01-01
Lantus	INSULIN GLARGINE	Sanofi	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	Insulin Analog [EPC]	Insulin receptor	1996-01-01
Humulin	insulin	Eli Lilly	Insulin Analog [EPC]	Tyrosine-protein kinase Lck	1982-01-01
Farxiga	Farxiga	AstraZeneca		Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1
Humalog	Humalog	Halozyme Therapeutics		Insulin receptor
Lantus	Lantus	Rijnstate Hospital		Insulin receptor
Lyumjev	Lyumjev	McGill University Health Centre/Research Institute of the McGill University Health Centre		Insulin receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 2 drugs in Diabetes mellitus type 1
Eli Lilly · 2 drugs in Diabetes mellitus type 1
Astrazeneca Ab · 1 drug in Diabetes mellitus type 1
Halozyme Therapeutics · 1 drug in Diabetes mellitus type 1
Lexicon Pharms Inc · 1 drug in Diabetes mellitus type 1
McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in Diabetes mellitus type 1
MedImmune LLC · 1 drug in Diabetes mellitus type 1
PROVENTION BIO INC · 1 drug in Diabetes mellitus type 1
Provention Bio Inc · 1 drug in Diabetes mellitus type 1
Rijnstate Hospital · 1 drug in Diabetes mellitus type 1
· 1 drug in Diabetes mellitus type 1
Sanofi · 1 drug in Diabetes mellitus type 1

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Diabetes mellitus type 1:

Cite this brief

Drug Landscape (2026). Diabetes mellitus type 1 — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diabetes-mellitus-type-1. Accessed 2026-06-10.

Diabetes mellitus type 1 full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing